|
Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Takeda |
Patents, Royalties, Other Intellectual Property - Amgen; Columbia University Medical Center (Inst) |
Travel, Accommodations, Expenses - Perkin Elmer |
|
Kimberly Mayumi Komatsubara |
Consulting or Advisory Role - Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Michael J. Hennessy Associates; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Prometheus |
|
|
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Iconic Therapeutics; Janssen Oncology; Merck; Novartis |
|
|
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics |
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech |
Research Funding - Astex Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology) |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen; Intensity Therapeutics |
Patents, Royalties, Other Intellectual Property - Amgen; OmniSeq |
Travel, Accommodations, Expenses - Rockpointe |